Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Core Insights - Annexon, Inc. is advancing a late-stage clinical platform for novel therapies targeting classical complement-mediated neuroinflammatory diseases, with a focus on geographic atrophy (GA) [1][7] - The company presented findings on its investigational therapy ANX007 at the Macula Society 48th Annual Meeting, highlighting its potential in vision preservation [1][2] Product Overview - ANX007 is a first-in-kind, non-pegylated antigen-binding fragment designed to block C1q locally in the eye, showing significant vision preservation in GA patients [2][3] - The therapy demonstrated statistically significant protection against vision loss in the Phase 2 ARCHER trial, with a notable treatment effect that increased over time [5] Clinical Trial Details - The Phase 2 ARCHER trial was randomized, multi-center, double-masked, and sham-controlled, showing consistent protection against vision loss across multiple measures [5] - ANX007 provided significant protection from vision loss as measured by best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), with a treatment effect that was time and dose-dependent [5] Regulatory Designations - ANX007 has received Fast Track designation from the FDA and Priority Medicine (PRIME) designation in the EU, indicating its potential therapeutic advantage [4] Mechanism of Action - ANX007 selectively inhibits C1q, a key driver of neurodegeneration, preventing aberrant activation of the classical complement pathway that leads to vision loss [3][4] - The therapy has shown to protect retinal structures critical for vision, including photoreceptors and retinal pigment epithelial cells [5]